These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2057456)

  • 1. Non-clinical local tolerance testing of medicinal products. CPMP Working Party on Safety of Medicinal Products.
    Pharmacol Toxicol; 1991 Mar; 68(3):233-6. PubMed ID: 2057456
    [No Abstract]   [Full Text] [Related]  

  • 2. Reproductive toxicology guidelines: comparison and application.
    Beltrame D; Mazué G
    Ann Ist Super Sanita; 1993; 29(1):3-14. PubMed ID: 8129269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.
    Robertson JS; Cichutek K
    Dev Biol (Basel); 2000; 104():53-6. PubMed ID: 11713824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar biological medicinal products currently licensed in the European union--overview of non-clinical study programs.
    Heim HK
    Biologicals; 2011 Sep; 39(5):284-8. PubMed ID: 21871818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Toxicologic studies subjected to critical evaluation].
    Wilmer JW
    Tijdschr Diergeneeskd; 1987 Jun; 112(11):685-6. PubMed ID: 3603537
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety pharmacology: an essential interface of pharmacology and toxicology in the non-clinical assessment of new pharmaceuticals.
    Claude JR; Claude N
    Toxicol Lett; 2004 Jun; 151(1):25-8. PubMed ID: 15177637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemical compound safety: typology of competency accreditation for assay centers and analytical laboratories].
    Menditto A; Chiodo F
    Ann Ist Super Sanita; 2002; 38(1):77-85. PubMed ID: 12122899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-clinical safety studies on biosimilar recombinant human erythropoietin.
    Parnham MJ; Schindler-Horvat J; Kozlović M
    Basic Clin Pharmacol Toxicol; 2007 Feb; 100(2):73-83. PubMed ID: 17244255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Draft guidelines on mutagenicity testing of new drugs issued by the CPMP. A four test screen.
    Draper MH; Griffin JP
    Arch Toxicol; 1980 Nov; 46(1-2):9-19. PubMed ID: 7236001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Note for guidance. Production and quality control of cytokine products derived by biotechnological processes. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Apr; 19(2):125-31. PubMed ID: 1888491
    [No Abstract]   [Full Text] [Related]  

  • 12. Do natural compounds need specific drug development?
    Simon P; Verry M
    Prog Clin Biol Res; 1988; 280():407-21. PubMed ID: 3051029
    [No Abstract]   [Full Text] [Related]  

  • 13. European Drug Master File procedure for active ingredients. CPMP Working Party on Quality of Medicinal Products.
    Pharmacol Toxicol; 1991 Jan; 68(1):75-6. PubMed ID: 2008417
    [No Abstract]   [Full Text] [Related]  

  • 14. Comments on the assessment of neurotoxicity in routine toxicity studies.
    Schaeppi U
    Zentralbl Bakteriol Mikrobiol Hyg B Umwelthyg Krankenhaushyg Arbeitshyg Prav Med; 1987 Oct; 185(1-2):65-8. PubMed ID: 3124391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Note for guidance. Production and quality control of human monoclonal antibodies. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Apr; 19(2):133-8. PubMed ID: 1888492
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of user safety, exposure and risk to veterinary medicinal products in the European Union.
    Woodward KN
    Regul Toxicol Pharmacol; 2008 Feb; 50(1):114-28. PubMed ID: 18060673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Union revamps toxicology testing in attempt to limit animal use, improve prediction.
    Sinha G
    J Natl Cancer Inst; 2006 Jun; 98(11):728-9. PubMed ID: 16757693
    [No Abstract]   [Full Text] [Related]  

  • 19. Requirements of preclinical examinations.
    Lehnert T; Ulbrich B
    Lens Eye Toxic Res; 1990; 7(3-4):207-19. PubMed ID: 2100159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.